UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~October~~ ~~26,~~December 31, 2009

HemoBioTech, Inc. ~~(Exact Name of Company as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation)~~

(Exact Name of Company as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-51334	33-0995817
(Commission File Number)	(IRS Employer Identification No.)

5001 Spring Valley Road

Suite 1040 – West

	Dallas, TX	75244
	(Address of Principal Executive Offices)	(Zip Code)

Dallas TX 75244

(~~972)~~Address ~~455-8950~~of Principal Executive Offices) (~~Company’s~~Zip ~~Telephone Number, Including Area~~ Code) ~~(Former Name or Former Address, if Changed Since Last Report)~~

(972) 455-8950

(Company’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(ab) ~~Appointment~~On ofDecember ~~Chairman~~31, 2009, Mark Rosenblum resigned as Chief Financial Officer and Secretary of HemoBioTech, Inc. (the ~~Board~~“Company”) in order to pursue another opportunity.

~~The~~(c) On January 1, 2010, the Board of Directors of ~~HemoBioTech, Inc. (~~the “Company”), ~~elected~~appointed Robert ~~Baron~~Comer as ~~the new~~Interim ~~Chairman~~Chief ofFinancial ~~the~~Officer. ~~Board~~Mr. ofComer, ~~Directors~~an ~~effective~~independent ~~October~~director ~~26,~~of ~~2009~~the Company, ~~replacing~~had ~~Dr. Arthur~~previously P.served ~~Bollon~~as Interim CFO.

DrRobert Comer, age 77, has served as a director of the Company since April 6, 2005. Mr. Comer had served as ~~Bollon~~Chairman ~~will~~of ~~continue~~the Audit Committee and is a member of the Nominating and Corporate Governance Committee. From 1994 to ~~remain~~the present, Mr. Comer has been involved in contract consulting and served as the ~~President~~Company’s Acting Chief Financial Officer between November 18, 2004 and April 1, 2005. From 1991 to 1994, he served as Chief ~~Executive~~Financial Officer of Banc One Management and Consulting Corporation. From 1987 to 1991, Mr. Comer was Managing Partner of Robert W. Comer & Associates. From 1985 to 1987, Mr. Comer was a Director of ~~the~~Financial ~~Company~~Management Services of InterFirst Corporation. From 1969 to 1981, Mr. Comer was an audit partner with Arthur Andersen & Co. Mr. Comer received his B.S. and M.B.A. degrees from Indiana University.

~~Pursuant to~~There ~~the~~were ~~Company's~~no ~~Bylaws,~~transactions ~~Mr.~~since ~~Baron~~January ~~will~~1, ~~preside~~2009, ator ~~all~~any ~~meetings~~currently ofproposed ~~the shareholders~~transaction ~~and~~between atthe ~~all~~Company ~~meetings~~and ofin ~~the~~which ~~Board of Directors~~Mr. ~~Robert~~Comer ~~Baron~~had ~~has been~~ a ~~director~~direct ofor ~~the~~indirect ~~Board~~material ~~since December 2004~~interest.

Item 9.01. Financial Statements and Exhibits.

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

		HEMOBIOTECH, INC.
Date: October 29, 2009
	By:	/s/ Arthur P. Bollon
		Arthur P. Bollon, PhD.
		Chairman, President, Chief Executive Officer

Date: January 6, 2010 HEMOBIOTECH, INC.

By: /s/ Arthur P. Bollon____________________

Arthur P. Bollon, PhD.

Chairman, President, Chief Executive Officer

Filing Compare · HEMOBIOTECH, INC.